Current role and future developments of radiotherapy in early-stage favourable Hodgkin's lymphoma.
Eich
Hans Theodor
HT
Department of Radiation Oncology, University of Cologne, Radiotherapy Reference Center of the German Hodgkin Study Group (GHSG), Germany.
Müller
Rolf-Peter
RP
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005500:Follow-Up Studies; D005544:Forecasting; D006689:Hodgkin Disease / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008198:Lymph Nodes / Q000528:radiation effects; D009367:Neoplasm Staging; D011446:Prospective Studies; D011785:Quality Assurance, Health Care; D011878:Radiotherapy / Q000592:standards; D011879:Radiotherapy Dosage; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D017211:Treatment Failure; D016896:Treatment Outcome; D014747:Vinblastine / Q000627:therapeutic use
D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin